NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

G7 Freedom Constrained Vivacit-E Liners
G7 Freedom Constrained Vivacit-E Liners

NCT05587244

Enrolling By InvitationNA

Sponsor: Zimmer Biomet

Conditions: Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures, Femoral Neck Fractures

Interventions: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners

Countries: United States

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Patient is 18 to 80 years of age, inclusive
* Patient is skeletally mature
* Patient qualifies for unilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:

  * Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
  * Rheumatoid arthritis
  * High risk for dislocation
  * Undergoing revision hip arthroplasty
  * Correction of functional deformity
  * In need of treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
* Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
* Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB approved informed consent

Exclusion Criteria:

* Patient is septic, has an active infection or has osteomyelitis at the affected joint
* Patient has significant osteoporosis as defined by treating surgeon
* Patient has metabolic disorder(s) which may impair bone formation
* Patient has osteomalacia
* Patient has distant foci of infections which may spread to the implant site
* Patient has rapid joint destruction, marked bone loss or bone resorption on pre-operative radiographs
* Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
* Patient is undergoing simultaneous bilateral THA
* Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which might jeopardize the outcome of the surgery.
* In the opinion of the investigator, patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
* Patient is known to be pregnant
* The patient is in the vulnerable population group, such as

  * a prisoner
  * a known alcohol or drug abuser
  * mentally incompetent or unable to understand what participation in this study entails
Locations (10)
  • Birmingham, Alabama, United States
  • Los Angeles, California, United States
  • Gainesville, Florida, United States
  • Livingston, New Jersey, United States
  • Columbus, Ohio, United States
  • Knoxville, Tennessee, United States
  • Houston, Texas, United States
  • Plano, Texas, United States
  • Salt Lake City, Utah, United States
  • Morgantown, West Virginia, United States